REMEDI4ALL **FUNDERS NETWORK**

CONNECTING FUNDERS TO MAXIMISE THE POTENTIAL OF DRUG REPURPOSING RESEARCH

REMEDI4ALL **FUNDERS NETWORK**

Distribution of funders within the network





REMEDI4ALL **FUNDERS NETWORK**

Distribution of funders within the network

Type of organisation



Source of funding



Experience in funding DR research



NGO = Non-Governmental Organisation, DR = Drug Repurposing

Agenda

Time	Topic
15.15 – 15.25	**Welcome & festive opening**
15.25 – 15.40	**REMEDi4ALL Funders Network – facts & practicalities** – *Heleen van der Meer (ZonMw)*
15:40-16:50	**REMEDi4ALL services for funders and how to be involved** – *All* Interactive session to discuss how REMEDi4ALL can support funders, focusing on: • **Funding opportunities & innovative funding models** – *Pan Pantziarka (Anticancer Fund) & Heleen van der Meer (ZonMw)* • **Assessment framework for funding drug repurposing projects** – *Dalma Hosszú (Syreon Research Institute)* • **Policy barriers to drug repurposing**– *Zsuzsanna Petykó (Syreon Research Institute)* • **Training** – *Rick Thompson (Beacon)*
16:50-17:00	**Wrap-up** – *REMEDi4ALL*

REPURPOSING OF MEDICINES 4ALL

The European Platform for Medicines Repurposing

Funders network - facts & practicalities

Heleen van der Meer (ZonMw)

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.
Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

REMEDi4ALL Funders Network

- A dynamic international network comprising diverse funders who are committed to drive drug repurposing forward.
- An inclusive forum for discussion (think tank), where we encourage you to share your funding perspective and actively engage in conversations surrounding policy matters and potential solutions to enhance the field.
- Established in October 2023 as part of EU-funded project REMEDi4ALL (R4ALL)
- Led by R4ALL partners ZonMw & the Anticancer Fund
- Charter – document describing purpose, background, objectives etc of network
- Membership application form signed to join the network
- 27 members & 4 observers (status 1 March 2024) – more funders are welcome to join
- No financial or legal commitment
- We are not a funding entity

Contact

- Communication through email, R4ALL newsletter & socials
- Information about meetings, tools & resources on our webpage: https://remedi4all.org/funders-network/
- Questions – email REMEDi4ALL@zonmw.nl
- At least yearly (hybrid) meeting + online workshop

Our aims

facilitate collaboration among funders and other stakeholders

share best funding practices



reduce fragmentation of the drug repurposing funding landscape

create innovative funding streams and explore viable business models

provide a marketplace for funding opportunities, including joint calls



find solutions for funding barriers

advocate for policy changes that hamper drug repurposing

Activities so far



REPURPOSING OF MEDICINES 4ALL

The European Platform for Medicines Repurposing

Services for funders and how to be involved

REMEDi4ALL team

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.
Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

WP10 – CLINICAL & NON-CLINICAL DEMONSTRATORS

TRANSVERSAL

WP1 – PATIENT & USER ENGAGEMENT, ONBOARDING & CO-CREATION PATHWAY

WP2 – USER PROJECT PROFILING & OPERATIONS (REGULATORY PLANNING)

WP3 – TRAINING & CAPACITY BUILDING

DISCOVERY

WP4 – RESEARCH DATA, TOOLS & IN SILICO DISCOVERY

WP5 – IN VITRO SERVICES

DEVELOPMENT

WP6 – PRECLINICAL DEVELOPMENT & VALIDATION

WP7 – CLINICAL DEVELOPMENT & IMPLEMENTATION

PRACTICE

WP8 – IMPROVING THE MARKET ACCESS ENVIROMENT OF DR

WP9 – FUNDERS NETWORK & RESEARCH FUNDING POLICY

WP11 – BUSINESS PLANNING & COMMUNICATION

WP12 – INTERNATIONALIZATION & NETWORKING

WP13 – PROJECT MANAGEMENT

RESEARCHERS

PATIENTS

HEALTH CARE SYSTEM

PAYERS

PUBLIC SECTOR

PHARMACEUTICAL INDUSTRY

POLICY-MAKERS

WP9 Contributors

REPURPOSING OF MEDICINES 4ALL

ZonMw

Anticancer Fund

syreon Research Institute

medicines for europe
better access. better health.

beacon for rare diseases

EURORDIS RARE DISEASES EUROPE

Dompé

ecrin

eatris

Overview of deliverables and milestones



We want to hear from you!

We aim to create a range of incentives, funding opportunities and services to support you.

- Where do you want to be involved?
- What examples or best practices can you share?
- What are your needs?
- What is missing?

REPURPOSING OF MEDICINES 4ALL

The European Platform for Medicines Repurposing

Funding opportunities & innovative funding models

Pan Pantziarka (Anticancer Fund) & Heleen van der Meer (ZonMw)

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.
Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

Funding Radar – online match-making





The Funding Radar is an online database, hosted on the REMEDi4ALL website, that contains details of open funding calls that include drug repurposing projects

- Open access – no membership fees
- Includes filters by project category, disease area, geography etc.
- Supports email alerts for new funding calls
- Designed for funders and applicants interested in repurposing rather than general funding calls

The Funding Radar will include projects that cover the full life-cycle – from preclinical work right through to clinical trials and beyond

Current status and next steps



- Data for open calls from all Funders Network members being collated and entered into the database
- Functionality implemented and site ready to go live
- We want to incorporate the Funding Radar into the workflow for new calls
- Publicise to additional funders and to potential applicants from clinical, academic and patient advocacy worlds

https://remedi4all.org/funding-calls-overview/

Help us make this service to the repurposing community a successful tool!

We will create funders network think tanks

- Group of people who work together on common issue/topic
- Regular online meetings
- Share & discuss best practices
- Explore solutions
- Make recommendations, e.g. to policy makers
- Report back to funders network in best practice workshop
- Provide input into R4ALL deliverables, such as report on innovative co-funding models (WP9) & policy recommendations (WP8)
- Provide input for policy discussion (WP8, Policy Board)

Join our funders network think tanks on

Innovative funding models

Background: funding repurposing is hard because of market failure / exclusivity / licensing issues

Aim:

- Create / generate new funding streams/funds
- Share ideas & best practices (worldwide)
- Look at solutions in literature
- Examples: DRUP Trial (NL), Prize funds, NHS drug repurposing programme, collaborations with payer

Join our funders network think tanks on

Joint calls between funders

Background: Running joint calls is complex and difficult, e.g. legal, organizational, cross border issues

Aim:

- Very practical → discuss and share best practices on how to perform joint calls
- We will provide template materials to facilitate the creation for joint calls e.g. Template Call text, Guidelines for applicants (if needed), Preproposal format (if applicable), Full proposal format, Governance of the Call, Memorandum of Understanding, Joint Controller Agreement → Guiding document due Sept 2024
- Find synergy with other projects/partnerships such as ERA4Health, ERDERA, ATTRACT
- Explore funding policy changes to encourage more joint calls

REPURPOSING OF MEDICINES 4ALL

The European Platform for Medicines Repurposing

Assessment Framework for funding Drug Repurposing projects

Dalma Hosszú (Syreon Research Institute)

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.
Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

Process of developing a standardized tool for the assessment



Involvement of REMEDI4ALL Funders Network

- Presenting criteria list with definitions at Funders Workshop in June 2024
- Challenge Meeting: dedicated event for funders as an interactive workshop to collect detailed feedback on assessment criteria + definitions + metrics and measures – Q3 2024
- Testing period on real-life or hypothetical DR cases with interactive collaboration before launch of the final tool

REPURPOSING OF MEDICINES 4ALL

The European Platform for Medicines Repurposing

WP8: Policy barriers to drug repurposing

Zsuzsanna Petykó (Syreon Research Institute)

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.
Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

Barriers to drug repurposing

Source	Data retrieved from	No. of mentions of barriers collected
Systematic review (Embase & Pubmed)	**141** publications	**485**
Snowball search	**10** publications	**57**
Grey literature search	**39** documents	**109**
Interviews	**24** interviews	**119**

770 explicit mentions of barriers

(still containing duplicates)

Thematic analysis

33 barriers in 9 topics

Main topics of barriers

1. Perception of drug repurposing
2. Business case for repurposing on-patent medicines
3. Business case for repurposing off-patent medicines
4. Non-industry-funded DR
5. Ecosystem for DR outside big pharma companies

6. Market authorisation	7. Market exclusivity, IP and off-label use	8. Health technology assessment	9. Pricing and reimbursement

Involvement of REMEDI4ALL Funders Network

April/May 2024: Think tank on barriers to DR

- The list of barriers should reflect the **current policy problems**
- It needs to be validated by different stakeholder groups, **including the funders!**

Aim:
To review and modify the list of barriers collected from the literature
(review structure, wording, add or delete barriers)

June 2024: Online policy survey to prioritise barriers

- A wide range of barriers were identified, and we would like to focus the project resources on the **most relevant ones**
- Participants will be asked to rank the final barriers on their **impact and actionability**

REPURPOSING OF MEDICINES 4ALL

The European Platform for Medicines Repurposing

Developing a repurposing curriculum: supporting funding and funders

Rick Thompson (Beacon)

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.
Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

The REMEDi4LL repurposing curriculum...



REPURPOSING OF MEDICINES 4ALL

A tool to support outcomes focussed research in repurposing

All about funding

The Funding Module



0. Welcome to Introduction
1. The DR funding landscape in the EU and UK

- Do you like the structure of this part of the module?
- Is there anything major missing?
- Would you be willing to join a discussion or focus group to share your thoughts on training for funders?

0. Welcome to Funding for Funders
1. The importance of drug repurposing and why you should fund it
2. How to fund drug repurposing
3. Joint funding in drug repurposing
4. Setting Gold Standard expectations: What does a good project need?
5. Assessing applicants and selecting the best opportunities for you
6. Funding as a patient organisation

The Funding Module



0. Welcome to The Funding Landscape for Applicants and Finding Opportunities
1. Different funding opportunities
2. Connecting with funders/how to connect with funders
3. costing your research
4. Funding agreements

0. Welcome to Applying for Funding
1. Creating a strategy
2. Writing a gold standard grant application
3. Using preclinical data in your application
4. Using research results in your application
5. Showcasing Patient engagement in your application
6. Market authorisation, reimbursement & HTA
7. Considering Intellectual Property in your application

- Do you like the structure of this part of the module?
- Is there anything major missing?
- Would you be willing to join a discussion or focus group to share your thoughts on training for those applying for funding?

Developing the training

We will be working in collaboration with the other REMEDi4ALL work packages to share their outputs through our training platform – expect to see outcomes from the **Assessment framework** and **joint funding calls** work here.

Questions

- What are the biggest mistakes you see funding applicants make?
- What are your biggest challenges when looking to fund a repurposing project?
- What are the unique challenges to funders of different sizes, and different sectors?

REPURPOSING OF MEDICINES 4ALL

The European Platform for Medicines Repurposing

Wrap up

REMEDi4ALL team

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.
Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

R4ALL services for funders and how to be involved

- R4ALL is creating a range of incentives, funding opportunities and services to support you!
- **Contribute and give input into:**
  - Funding radar – share (active) calls [https://remedi4all.org/funding-calls-overview/]
  - Assessment Framework for drug repurposing projects – through workshop June 2024 + challenge meeting Q3 2024
  - Training - through 1-2 focus group meetings
- **Join the think tank on innovate funding models**
  - to create new funding streams
- **Join the think tank on joint calls**
  - to share & discuss best practices
- **Join the think tank on policy barriers**
  - April/May think tank to validate list of barriers
  - Followed by online survey to prioritize barriers in June
- Let us know - what other needs do you have?

Upcoming funders network events
- Workshop (online) June/July 2024
- Best practice workshop (in person & online) in Q1/Q2 2025

Post meeting survey - REMEDi4ALL Funders Network meeting 07 March 2024

‘Medicines Reimagined’ Stakeholder Forum

We are a dynamic **global community** advancing drug repurposing through discussion, collaboration and knowledge exchange. Doors are open to all stakeholders who are passionate about the transformative potential of drug repurposing and wish to be part of this vibrant community of practice.

Researchers, patients/carers, consultants, CROs, patient groups/charity representatives, regulators, healthcare providers, industry professionals, funding organisations and policy makers are welcome to join the ‘Medicines Reimagined’ Stakeholder Forum in LinkedIn.

Scan this QR code and start being part of the conversation

REPURPOSING OF MEDICINES 4ALL

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057442.

Thank you !
We look forward to collaborating !

For questions - REMEDi4ALL@zonmw.nl

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.
Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union, who cannot be held responsible for them.
This presentation reflects only the author's view. The EU is not responsible for any use that may be made of the information it contains.